Corresponding Author: Gabriella Gobbi, MD, PhD, Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, 1033 Pine Ave W, Ludmer Research and Training Building, Ste 220, Montreal, QC H3A 1A1, Canada (gabriella.gobbi@mcgill.ca).
Published Online: February 13, 2019. doi:10.1001/jamapsychiatry.2018.4500
Correction: This article was corrected on March 13, 2019, for incorrect information in the Discussion section.
Accepted for Publication: November 26, 2018.
Author Contributions: Dr Gobbi had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Gobbi, Atkin, Boruff, Ware, Mayo.
Acquisition, analysis, or interpretation of data: Gobbi, Atkin, Zytynski, Wang, Askari, Boruff, Cipriani, Marmorstein, Dendukuri, Mayo.
Drafting of the manuscript: Gobbi, Atkin, Zytynski, Askari, Boruff, Ware, Cipriani, Dendukuri.
Critical revision of the manuscript for important intellectual content: Gobbi, Atkin, Wang, Askari, Cipriani, Marmorstein, Dendukuri, Mayo.
Statistical analysis: Wang, Askari, Cipriani, Marmorstein, Dendukuri, Mayo.
Obtained funding: Gobbi, Mayo.
Administrative, technical, or material support: Gobbi, Atkin, Zytynski, Ware.
Supervision: Gobbi, Atkin, Cipriani, Mayo.
Conflict of Interest Disclosures: Dr Gobbi received a grant (which was not related to this meta-analysis) for the study of cannabidiol in neuropathic pain by the Quebec Ministry of Economy, Science and Innovation with the participation of Aurora Cannabis Inc. As of July 1, 2018, Dr Ware has been employed by Canopy Growth Corporation, a Canadian-licensed cannabis producer; this affiliation was disclosed at the time of the appointment, and his involvement in the study was prior to all discussions about this appointment. No other conflicts were reported.
Funding/Support: This research was funded by the Canadian Institutes of Health Research (knowledge synthesis grant 147991) and the Quebec Network on Suicide, Mood Disorders and Related Disorders. Dr Cipriani’s work in this article was supported by the National Institute for Health Research (NIHR) Oxford Cognitive Health Clinical Research Facility, by an NIHR Research Professorship (grant RP-2017-08-ST2-006) and by the NIHR Oxford Health Biomedical Research Centre (grant BRC-1215-20005).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The views expressed are those of the authors and not necessarily those of the UK National Health Service, the National Institute for Health Research, or the UK Department of Health.
Additional Contributions: We thank Nazi Torabi, MLIS (St Michael’s Hospital, Toronto), for the peer review of the Medline search strategy. No compensation was received.
1. World Drug Report. Vienna, Austria: United National Office on Drugs and Crime; 2017.
4.Johnston
LD. OMP, Bachman J, Schulenberg J. Monitoring the Future National Results on Drug Use: 2012 Overview. Ann Arbor, Michigan: Institute for Social Research, University of Michigan; 2013.
6.Australian Institute of Health and Welfare (AIHW). 2010 National Drug Strategy Household Survey Report. Canberra, Australia: Australian Institute of Health and Welfare; 2011.
7.Fuller
E, Hawkins
V. Smoking, drinking and drug use among young people in England in 2011. London, UK: Health and Social Care Information Centre; 2012.
8. European Drug Report 2018: Trends and Developments. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2018.
13.National Academies of Sciences. The Health Effects of Cannabis and Cannabinoids: the Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017.
14.Paton
S, Kessler
R, Kandel
D. Depressive mood and adolescent illicit drug use: a longitudinal analysis.
J Genet Psychol. 1977;131(2d Half):267-289.
PubMedGoogle ScholarCrossref 25.Eden
J, Levit
L, Berg
A, Morton
S. Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: National Academies Press; 2011.
27.McGowan
J, Sampson
M, Lefebvre
C. An evidence based checklist for the peer review of electronic search strategies (PRESS EBC).
Evid Based Libr Inf Pract. 2010;5(1):149-154. doi:
10.18438/B8SG8RGoogle ScholarCrossref 28.Canadian Agency for Drugs and Technologies in Health. Grey Matters: a Practical Search Tool for Evidence-Based Medicine. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2013.
36.D’Amico
EJ, Tucker
JS, Miles
JN, Ewing
BA, Shih
RA, Pedersen
ER. Alcohol and marijuana use trajectories in a diverse longitudinal sample of adolescents: examining use patterns from age 11 to 17 years.
Addiction. 2016;111(10):1825-1835. doi:
10.1111/add.13442PubMedGoogle ScholarCrossref 49.Briere
FN. Association Entre Consommation de Drogues Illicites et Symptomatologie Dépressive à l’Adolescence. Une Étude Longitudinale Auprès de Jeunes Québécois Fréquentant l’École Secondaire en Milieu Défavorisé [PhD thesis]. Montreal, Canada: Université de Montréal; 2011.
55.Scholes-Balog
KE, Hemphill
SA, Evans-Whipp
TJ, Toumbourou
JW, Patton
GC. Developmental trajectories of adolescent cannabis use and their relationship to young adult social and behavioural adjustment: a longitudinal study of Australian youth.
Addict Behav. 2016;53:11-18. doi:
10.1016/j.addbeh.2015.09.008PubMedGoogle ScholarCrossref 61.Womack
SR, Shaw
DS, Weaver
CM, Forbes
EE. Bidirectional associations between cannabis use and depressive symptoms from adolescence through early adulthood among at-risk young men.
J Stud Alcohol Drugs. 2016;77(2):287-297. doi:
10.15288/jsad.2016.77.287PubMedGoogle ScholarCrossref 62.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
65.Lipsey
MW, Wilson
DB. Practical Meta-analysis. Thousand Oaks, CA: Sage Publications; 2001.
71.Brody
DJ, Pratt
LA. J H. Prevalence of depression among adults aged 20 and over: United States, 2013–2016. Hyattsville, MD: National Center for Health Statistics; 2018.
72.Vespa
J. The Changing Economics and Demographics of Young Adulthood: 1975-2016. Suitland, MD: US Department of Commerce Economics and Statistics Administration, US Census Bureau; 2017.
75.Rubino
T, Realini
N, Braida
D,
et al. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood.
Hippocampus. 2009;19(8):763-772. doi:
10.1002/hipo.20554PubMedGoogle ScholarCrossref 77.Faggiano
F, Vigna-Taglianti
FD, Versino
E, Zambon
A, Borraccino
A, Lemma
P. School-based prevention for illicit drugs’ use.
Cochrane Database Syst Rev. 2005;(2):CD003020.
PubMedGoogle Scholar